KETAMINE ( DrugBank: Ketamine )

6 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	3
13	Multiple sclerosis/Neuromyelitis optica	2
70	Spinal stenosis	4
113	Muscular dystrophy	1
156	Rett syndrome	1
215	Tetralogy of Fallot	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-000041-40-NL (EUCTR)	22/02/2022	10/11/2021	A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action	A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action - Microdosing and Parkinson’s disease	Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Psilocybin INN or Proposed INN: Psilocybine Product Name: Ketamine INN or Proposed INN: KETAMINE	Maastricht University	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	34	Phase 2	Netherlands
2	NCT04944017 (ClinicalTrials.gov)	November 23, 2021	22/6/2021	Ketamine for the Treatment of Depression in Parkinson's Disease	Ketamine for the Treatment of Depression in Parkinson's Disease (KET-PD)	Parkinson's Disease;Depression	Drug: Ketamine Infusion;Other: Placebo - Saline Infusion	Yale University	Fox (Michael J.) Foundation for Parkinson's Research	Recruiting	40 Years	80 Years	All	56	Phase 2	United States
3	NCT04912115 (ClinicalTrials.gov)	October 5, 2021	25/5/2021	Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia	A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects With Parkinson's Disease	Dyskinesias;Movement Disorders;Central Nervous System Diseases;Nervous System Diseases;Neurologic Manifestations	Drug: Ketamine;Drug: Midazolam	PharmaTher Inc.	NULL	Suspended	30 Years	85 Years	All	30	Phase 2	United States

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05378100 (ClinicalTrials.gov)	January 1, 2023	12/5/2022	Ketamine for Multiple Sclerosis Fatigue	Low-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue (INKLING-MS)	Multiple Sclerosis Fatigue	Drug: Ketamine;Drug: Midazolam	Johns Hopkins University	United States Department of Defense	Recruiting	18 Years	65 Years	All	110	Phase 2	United States
2	NCT03500289 (ClinicalTrials.gov)	August 10, 2018	4/4/2018	Ketamine for Treatment of MS Fatigue	Ketamine for Treatment of Multiple Sclerosis-related Fatigue	Multiple Sclerosis;Fatigue	Drug: Ketamine;Drug: Midazolam	Johns Hopkins University	National Multiple Sclerosis Society	Completed	18 Years	65 Years	All	18	Phase 1/Phase 2	United States

70. Spinal stenosis

Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03088306 (ClinicalTrials.gov)	July 1, 2017	22/2/2017	Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients	Comparative Effectiveness of Multi-modal Pain Management Versus Standard Intra- and Post-operative Analgesia: Randomized Controlled Clinical Trial to Reduce Post-operative Pain and Opioid Use Among Patients Undergoing Lumbar Spine Surgery	Lumbar Spinal Stenosis;Lumbar Spinal Instability;Lumbar Spine Degeneration	Drug: Standard analgesia use [Oxygen];Drug: Standard analgesia use [Hydromorphone];Drug: Standard analgesia use [Volatile Anesthesia];Drug: Standard analgesia use [Fentanyl];Drug: Multi-modal pain management [Acetaminophen + Gabapentin];Drug: Multi-modal pain management [Fentanyl];Drug: Multi-modal pain management [Intravenous Ketamine];Drug: Multi-modal pain management [Valium + Gabapentin]	Johns Hopkins University	North American Spine Society	Completed	18 Years	100 Years	All	49	Early Phase 1	United States
2	EUCTR2016-002887-14-FI (EUCTR)	31/10/2016	14/10/2016	Dose-response of ketamine in patient controlled analgesia in orthopaedic surgery patients	Dose response study of Patient Controlled Analgesia (PCA) of S-ketamine in orthopaedic spine surgery patients - DoseRespKeta	Patients who are scheduled for elective posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation MedDRA version: 19.0;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]	Trade Name: Ketanest-S INN or Proposed INN: KETAMINE Trade Name: Oxycodone Orion INN or Proposed INN: OXYCODONE	University of Turku	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 1;Phase 4	Finland
3	EUCTR2012-000747-26-FI (EUCTR)	27/04/2012	02/04/2012	Ketamine to reduce postoperative pain in back surgery	Administration of S-Ketamine during spinal surgery to reduce postoperative pain	adult patients undergoing spinal surgery MedDRA version: 14.1;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]	Trade Name: Ketanest-S Product Name: Ketanest-S Other descriptive name: ESKETAMINE HYDROCHLORIDE	Helsinki Universiy Central Hospital	NULL	Not Recruiting			Female: yes Male: yes	192	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Finland
4	NCT01275547 (ClinicalTrials.gov)	January 2011	11/1/2011	The Analgesic Effect of Combined Treatment With Intranasal S-ketamine and Intranasal Midazolam	The Analgesic Effect of Combined Treatment With Intranasal S-Ketamine and Intranasal Midazolam Compared With Morphine Patient Controlled Analgesia in Spinal Surgery Patients	Analgesia, Patient-controlled;Spinal Stenosis	Drug: s-ketamine & midazolam;Drug: Morphine PCA	University Hospital, Basel, Switzerland	NULL	Completed	18 Years	N/A	Both	22	Phase 2/Phase 3	Switzerland

113. Muscular dystrophy

Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01645098 (ClinicalTrials.gov)	August 2011	8/6/2012	Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy	Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy	Drug: Ketamine;Drug: Dexmedetomidine	Nationwide Children's Hospital	NULL	Completed	N/A	N/A	Male	53	N/A	United States

156. Rett syndrome

Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03633058 (ClinicalTrials.gov)	March 12, 2019	8/8/2018	A Study to Evaluate Ketamine for the Treatment of Rett Syndrome	A Randomized, Double-blind, Placebo-controlled, Cross-over Study to Assess the Safety, Tolerability and Efficacy of Oral Ketamine for Patients With Rett Syndrome	Rett Syndrome	Drug: Ketamine	Rett Syndrome Research Trust	Vanderbilt University Medical Center	Completed	6 Years	12 Years	Female	24	Phase 2	United States

215. Tetralogy of Fallot

Clinical trials : 18 / Drugs : 26 - (DrugBank : 14) / Drug target genes : 13 - Drug target pathways : 45

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-IOR-16008571	2016-06-06	2016-05-31	Premedication for children with Tetralogy of Fallot	A comparative evalution of varies premedication regimes on children with Tetralogy of Fallot	Tetralogy of Fallot	oral dexmedetomidine:oral dexmedetomidine;oral ketamine:oral ketamine;oral dexmedetomidine mixed with ketamine:oral dexmedetomidine mixed with ketamine;	Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University	NULL	Recruiting			Both	oral dexmedetomidine:20;oral ketamine:20;oral dexmedetomidine mixed with ketamine:20;		China